Skip to content

递归制药

US · RXRX #2649 按市值排名 上市于 2021
3.47 -0.70 -16.71%
实时 - 追踪5344个代码 - 心跳于8秒前 · 2026-10-16 19:59

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了1家。
  • 机构持股总比例下降了5.1个百分点。

机构持股

机构持股比例
67.63% -5.14pp
机构数量
388 -1
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund52.35%
VC/PE Fund4.59%
Public Company4.44%
Individual/Insider2.98%
Hedge Fund2.91%
Sovereign Wealth Fund1.27%
Private Company1.12%
Family Office/Trust0.48%
Government Pension Fund0.34%
Other29.50%

主要股东 截至 2026-06-30

BlackRock 9.38% · 50.30M 股
ARK Investment Management LLC 7.71% · 41.34M 股
State Street Global Advisors 6.47% · 34.71M 股
Vanguard Portfolio Management, LLC 5.81% · 31.13M 股
Vanguard Capital Management, LLC 4.89% · 26.24M 股
Baillie Gifford 4.38% · 23.49M 股
Geode Capital Management, LLC 2.58% · 13.82M 股
SoftBank Group Corp. 2.54% · 13.64M 股
DCVC 2.54% · 13.62M 股
UBS Asset Management 1.81% · 9.71M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 11次买入 · 39次卖出

姓名职务持股比例
Blake Borgeson Co-Founder 1.13%
Christopher Gibson Chief Executive Officer 1.00%
Dean Li Co-Founder & Independent Director 0.60%
David Hallett Chief Scientific Officer 0.08%
Ben Taylor CFO & President of Recursion UK 0.06%
Najat Khan Chief R&D Officer, Chief Commercial Officer & Director 0.03%
Zavain Dar Independent Director 0.03%
Franziska Michor Director 0.02%
Robert Hershberg Independent Director 0.01%
Elaine Sun Director 0.00%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-30 Dean Li Co-Founder & Independent Director Other Acquisition +3,378 --
2026-09-30 Zavain Dar Independent Director Other Acquisition +4,607 --
2026-09-14 Ben Taylor CFO & President of Recursion UK Sale to Issuer -5,396 $3.41
2026-09-07 Najat Khan Chief R&D Officer, Chief Commercial Officer & Director Automatic Disposition -22,408 $3.52
2026-08-31 Blake Borgeson Co-Founder Automatic Disposition -30,000 $3.34
2026-08-20 Christopher Gibson Chief Executive Officer Intent to Sell (Form 144) -77,290 $3.39
2026-08-19 Christopher Gibson Chief Executive Officer Intent to Sell (Form 144) -75,000 $3.40
2026-08-18 Christopher Gibson Chief Executive Officer Intent to Sell (Form 144) -100,000 $3.28
2026-08-17 Christopher Gibson Chief Executive Officer Intent to Sell (Form 144) -26,806 $3.00
2026-08-16 Ben Taylor CFO & President of Recursion UK Sale to Issuer -25,018 $3.16
2026-08-16 David Hallett Chief Scientific Officer Sale to Issuer -26,657 $3.16
2026-08-16 Najat Khan Chief R&D Officer, Chief Commercial Officer & Director Sale to Issuer -80,498 $3.16
2026-08-12 Christopher Gibson Chief Executive Officer Intent to Sell (Form 144) -100,000 $3.31
2026-08-11 Christopher Gibson Chief Executive Officer Intent to Sell (Form 144) -50,000 $3.37
2026-08-09 Christopher Gibson Chief Executive Officer Intent to Sell (Form 144) -100,000 $3.27
2026-08-06 Christopher Gibson Chief Executive Officer Intent to Sell (Form 144) -100,000 $3.25
2026-08-03 Blake Borgeson Co-Founder Automatic Disposition -30,000 $3.25
2026-08-03 Christopher Gibson Chief Executive Officer Intent to Sell (Form 144) -75,000 $3.27
2026-07-29 Christopher Gibson Chief Executive Officer Intent to Sell (Form 144) -75,000 $3.00
2026-07-28 Christopher Gibson Chief Executive Officer Intent to Sell (Form 144) -50,000 $3.03

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:59:50 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

递归制药 讨论区 0 条评论

发表评论